Switzerland

The Swiss group is more than holding its own against Dupixent for prurigo nodularis and is looking to make further inroads into Sanofi and Regeneron's blockbuster's market share in atopic dermatitis.

With a “sharpened focus,” Polpharma Biologics has spun out its contract development and manufacturing business into a separate company.

The Swiss company remains bullish about the drug’s prospects for hidradenitis suppurativa but its stock has collapsed by 90% after hit-and-miss Phase III trial results.

Swiss medtechs have given overwhelming support for an ongoing bilateral approach between Switzerland and the EU, as proposed in the Swiss-EU Package in June. A medtech MRA is the ultimate prize, but that remains some way off.

The UDI devices module in swissdamed is now live and can be used on a voluntary basis until it becomes mandatory in mid-2026.

Generics Bulletin reviews global regulatory developments across the world.

In return for building a successful US export business, Switzerland has been handed a 39% tariff effective immediately by the Trump administration. Diplomatic channels have been reopened to undo the tariff. Meanwhile, the medtech industry is looking to develop OUS markets for Swiss exporters.

The US’ foreign trading partners are not working hard enough to secure bilateral deals, says US President Donald Trump, who will introduce new reciprocal tariffs on Aug. 7. MedTech Europe stresses that patients will suffer if medtech is not excluded from the tariffs.

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

NAD says Amazentis didn’t substantiate cellular performance and muscle function claims for its supplements containing proprietary ingredient Mitropure but provided “a sufficiently reliable and reasonable basis” for “clinically proven to revitalize mitochondria.”

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

The sector is continuing to show resilience despite financial and market challenges.